Journal of clinical psychopharmacology

Liver safety of ketamine and esketamine in hard-to-treat depression in real-world patients

Updated

Abstract

Chronic recreational ketamine abuse has been linked to cholestasis and cholangiopathy.

  • The safety profile of ketamine and esketamine for treatment-resistant depression is not well understood.
  • There is a concern that therapeutic use of these substances may pose similar risks to liver health as seen in recreational use.
  • Current knowledge lacks systematic data on liver enzyme changes or biliary injury associated with subanesthetic doses used in depression treatment.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free